CBD as possible help with lung damage in COVID-19 disease with protective peptides

Researchers at the Medical College of Georgia demonstrated earlier this year that CBD has the ability to improve oxygen levels and reduce inflammation and physical damage to the lungs associated with adult respiratory distress syndrome (ARDS). This new study has now shown the mechanisms behind these results, showing that CBD normalizes the levels of a peptide called apelin, which is known to reduce inflammation. The levels of this peptide are also low during the infection of COVID-19 .

Due to the lack of specific antiviral treatment and vaccination against COVID-19, it is absolutely essential to have an effective therapeutic modality to reduce hospitalization and mortality, as well as to improve the outcomes of patients infected with COVID-19 DISEASE. In a follow-up study to recent scientific findings that suggest the potential of cannabidiol (CBD) in the treatment of acute respiratory distress syndrome (ARDS), it is shown for the first time that CBD can alleviate the symptoms of ARDS through the regulation of apelin, a peptide with a significant role in central and peripheral immune regulation. CNS, metabolic and cardiovascular system. Interestingly, by intranasal administration of Poly (I:C), a synthetic viral dsRNA, there was a significant reduction in apelin expression in blood and lung tissues. CBD treatment was able to reverse the symptoms of ARDS towards normal levels. Importantly, CBD treatment significantly increased apelin expression, suggesting that the potential relationship between the apelinergic system and CBD may be a therapeutic target for the treatment of inflammatory diseases such as COVID-19 and many other pathological conditions. [1]

[1] Évila Lopes Salles, Hesam Khodadadi, Abbas Jarrahi, Meenakshi Ahluwalia, Valdemar Antonio Paffaro Jr, Vincenzo Costigliola, Jack C. Yu, David C. Hess, Krishnan M. Dhandapani, Babak Baban https://onlinelibrary.wiley.com /doi/10.1111/jcmm.15883